A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer.
Latest Information Update: 24 Dec 2013
At a glance
- Drugs Edotecarin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 17 Jan 2012 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 23 Aug 2007 Status change from in progress to completed.